Abstract
Etravirine (Intelence; Tibotec) is a non-nucleoside inhibitor of HIV-1 reverse transcriptase. In January 2008, it was approved by the US FDA for the treatment of HIV-1 infection in combination with other antiretroviral agents for treatment-experienced patients who have HIV-1 strains that are resistant to other drugs in this class.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Flexner, C. HIV drug development: the next 25 years. Nature Rev. Drug Discov. 6, 959–966 (2007).
Pauwels, R. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. Curr. Opin Pharmacol. 4, 437–446 (2004).
De Corte, B. L. From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. J. Med. Chem. 48, 1689–1696 (2005).
Andries, K. et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48, 4680–4686 (2004).
Food and Drug Administration. FDA labelling information [online], (2008).
Das, K. et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 47, 2550–2560 (2004).
Madruga, J. V. et al. Efficacy and safety of TMC125 (etravirine) in treatment experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370, 29–38 (2007).
Lazzarin, A. et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370, 39–48 (2007).
Vingerhoets, J. et al. Impact of baseline NNRTI mutations on the virological response to TMC125 (etravirine; ETR) in the DUET-1 and DUET-2 Phase III clinical trials. 11th European AIDS Conference P7.3/05 (Madrid, Spain, 2007).
Winters, B. et al. Development of vircoTYPE HIV-1 resistance analysis, including clinical cutoffs for TMC125, a new NNRTI. 15th Conference on Retroviruses and Opportunistic Infections Abstract 873 (Boston, USA, 2008).
Haubrich, R. et al. DUET-1 study group. DUET-1: Week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 612 treatment-experienced HIV-1-infected patients. 15th Conference on Retroviruses and Opportunistic Infections Abstract 790 (Boston, USA, 2008).
Woodfall, B. et al. Impact of NNRTI and NRTI resistance on the response to the regimen of TMC125 plus two NRTIs in Study TMC125-C227. 8th International Congress on Drug Therapy in HIV Infection PL5.6 (Glasgow, UK, 2006).
IMS Health, MIDAS Quantum (September 2007).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
R.H. has consulted for or received honorariums from Roche, Abbott Monogram, Merck, Schering, Bristol-Myers Squibb, Boeringher Ingelheim and Tanox. He has received research grant support (to UCSD) from GlaxoSmithKline, Abbott, Gilead, Pfizer and Tibotec.
R. H. would also like to acknowledge the following grant support for this work: CHRP-CH05-SD-607-005 and NIH-K24-AI064086.
Rights and permissions
About this article
Cite this article
Haubrich, R., Gubernick, S., Yasothan, U. et al. Etravirine. Nat Rev Drug Discov 7, 287–288 (2008). https://doi.org/10.1038/nrd2563
Issue Date:
DOI: https://doi.org/10.1038/nrd2563
